Sunway Biotech Co. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sunway Biotech Co. Ltd.
The development of oncolytic virus therapy has gained momentum over the past decade, due to its relatively safe mode of action and potential to enhance existing treatment options. A third of cancer vaccines in development are now oncolytic viruses, which are being developed for about 40 different types of cancer. In Vivo takes a closer look at therapies in development to see what the future holds for this promising therapy.
Early-stage venture capital funding in China continued to rise in Q3, while big Chinese companies are investing in foreign firms with an eye on access to new products and market expansion. Several healthcare funds were also set up to tap into emerging opportunities.
With new approaches in development that add or subtract genetic material to viruses, or arm them with immune-boosting proteins, oncolytic viruses may become the next modality for treating cancer. Several smaller companies and their backers – as well as those who have yet to invest in the space – eagerly await results from Amgen’s Phase III program OncoVex.
WuXi PharmaTech's spectacular public offering last summer piqued foreign investors' interest. Top tier VC firms are now investing in contract research organizations, manufacturing plays, and start-ups shifting business operations to China.